Aequus Enters Partnership to Improve Cannabinoid-Based Therapeutics

Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) announced a research collaboration with Canada’s national drug development and commercialization center, in order to determine pre-clinical safety and accuracy of cannabinoid-based therapeutics for various diseases.
As quoted in the press release:

Aequus has initiated a research program of cannabinoid-based therapeutics targeting neurological disorders. In 2016, Health Canada provided patients in Canada the ability to access cannabis for medical purposes when recommended by their physician. There are insufficient data, however, for proper therapeutic treatment protocols regarding the proper dosage and frequency for patients dealing with a wide variety of symptoms and disease areas. Aequus recently published a survey that confirms the medical need for improved clinical trial data supporting safety and efficacy of medical cannabis, reliability of dose delivery systems, high quality data collection tracking real world clinical outcomes, physician education, and quality controlled ingredients.
The goal of the Aequus/CDRD partnership is to address many of these deficiencies. The preclinical studies, including in-vitro and in-vivo toxicology, pharmacology, and formulation optimization in relevant disease models, will be conducted at CDRD’s facilities in Vancouver, BC, pending Health Canada approvals. This initial project leverages CDRD’s expertise in pre-clinical development and target validation for new products, and demonstrates CDRD’s ongoing engagement with life sciences companies in the Canadian marketplace. Products advanced through the collaboration will be commercialized by Aequus.

Click here to read the full press release.

Source: www.marketwired.com